Receptor News and Research

RSS

Cinnamon compound could be useful supplement to dexamethasone in COVID-19 treatment

Researchers in Germany and the United States have conducted a study showing that supplementing dexamethasone treatment with Ceylon cinnamon in cases of coronavirus disease 2019 (COVID-19) may allow dexamethasone to be administered at lower doses, thereby avoiding the side effects that occur with high doses of the steroid.

17 Jun 2021

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

The role of natural killer cells in fight against viral infections including SARS-CoV-2

In an effort to further understand the role of NK cells in combatting COVID-19, a group of researchers explored NK cells in acute viral infections, citing flavivirus and influenza virus infections as examples.

17 Jun 2021

Genetically engineering NK cells can destroy tumor-regenerating glioblastoma stem cells

Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted by natural killer (NK) cells, they are able to evade immune attack by releasing the TFG-β signaling protein, which blocks NK cell activity.

17 Jun 2021

Study may provide the basis to develop new therapies for urinary tract infections, kidney stones

The normal function of uromodulin, a protein that is made in the kidney and secreted into the urine, remains largely unknown. However, higher levels of uromodulin in the urine are related to lower rates of urinary tract infections and kidney stones, while higher levels of this protein in kidney cells are associated with higher rates of hypertension and chronic kidney disease.

17 Jun 2021

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).

17 Jun 2021

Could type III interferons be used as a SARS-CoV-2 therapeutic?

Researchers have found that both type I and type III interferons can inhibit SARS-CoV-2 infection in human intestinal cells, but type III interferons can act faster and for a longer period, making them suitable for potential therapeutics.

17 Jun 2021

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.

17 Jun 2021

How the common cold can provide protection against COVID-19

In a recent study, researchers found that prior infection with the rhinovirus can provide a more effective immune response against SARS-CoV-2 infection.

17 Jun 2021

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Study sheds new light on the function of a sight-saving growth factor

Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye.

17 Jun 2021

Different comorbid conditions in COVID-19 patients can impact outcomes of positive PCR test results

New study results indicate that different comorbid conditions affecting individuals diagnosed with COVID-19 may impact how long they continue to receive positive SARS-CoV-2 polymerase chain reaction (PCR) test results.

17 Jun 2021

Scientists decipher the activation mechanism of a chemokine receptor

Chemokine receptors, located at the surface of many immune cells, play an important role in their function. Chemokines are small proteins that bind to these receptors and control the movement and behavior of white blood cells.

16 Jun 2021

Long-term exposure to poor air quality increases COVID-19 risk, research finds

Even as governments across the United States consider lifting mask mandates and relaxing preventative measures as vaccination numbers creep up, new research from a UCLA-led team has found that such basic techniques significantly reduce the risk of getting COVID-19.

16 Jun 2021

Using natural killers from the immune system to target breast cancer cells

It sounds like a plot from a Quentin Tarantino movie -- something sets off natural killers and sends them on a killing spree.

16 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Cissampelos pareira (Cipa), also known as velvetleaf, is a widely used hormone modulator used to treat reproductive disorders and fever. Research has shown that it can inhibit three serotypes of Dengue virus (DENV) and affect various hormones.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

16 Jun 2021

Receptor News and Research

Cinnamon compound could be useful supplement to dexamethasone in COVID-19 treatment

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

The role of natural killer cells in fight against viral infections including SARS-CoV-2

Genetically engineering NK cells can destroy tumor-regenerating glioblastoma stem cells

Study may provide the basis to develop new therapies for urinary tract infections, kidney stones

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

Could type III interferons be used as a SARS-CoV-2 therapeutic?

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

How the common cold can provide protection against COVID-19

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Study sheds new light on the function of a sight-saving growth factor

Different comorbid conditions in COVID-19 patients can impact outcomes of positive PCR test results

Scientists decipher the activation mechanism of a chemokine receptor

Long-term exposure to poor air quality increases COVID-19 risk, research finds

Using natural killers from the immune system to target breast cancer cells

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News